Related references
Note: Only part of the references are listed.P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)
M. Hussain et al.
EUROPEAN UROLOGY SUPPLEMENTS (2013)
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
Tomohiro Kaku et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Nicolas Mottet et al.
EUROPEAN UROLOGY (2011)
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials
Paul L. Nguyen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand Tombal et al.
EUROPEAN UROLOGY (2010)
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
Per-Anders Abrahamsson
EUROPEAN UROLOGY (2010)
Current Approach to Androgen Deprivation Therapy in Patients With Advanced Prostate Cancer
Axel Heidenreich
EUROPEAN UROLOGY SUPPLEMENTS (2010)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?
Michel Bolla
EUROPEAN UROLOGY SUPPLEMENTS (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)
Fritz H. Schroder et al.
EUROPEAN UROLOGY (2009)
Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
Fernando E. C. Calais da Silva et al.
EUROPEAN UROLOGY (2009)
Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
Hendrik Isbarn et al.
EUROPEAN UROLOGY (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Targeting CYP17: established and novel approaches in prostate cancer
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Eric M. Horwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy
Juan Morote et al.
JOURNAL OF UROLOGY (2007)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
Edward M. Messing et al.
LANCET ONCOLOGY (2006)
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891
UE Studer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin sensitivity during combined androgen blockade for prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Intermittent androgen castration: A biological reality during intermittent treatment in metastatic prostate cancer?
N Mottet et al.
UROLOGIA INTERNATIONALIS (2005)
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor:: Results of European Organisation for the Research and Treatment of Cancer 30846 -: A phase III study
FH Schröder et al.
JOURNAL OF UROLOGY (2004)
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years
MP Wirth et al.
JOURNAL OF UROLOGY (2004)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails
W Kassouf et al.
JOURNAL OF UROLOGY (2003)
Hormonal therapy: Historical perspective to future directions
DG McLeod
UROLOGY (2003)
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: Updated results of a multicentric trial
F Boccardo et al.
EUROPEAN UROLOGY (2002)
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer
RW Ross et al.
JOURNAL OF UROLOGY (2002)
Decline in bilateral orchiectomy for prostate cancer in Olmsted County, Minnesota, 1956-2000
LJ Melton et al.
MAYO CLINIC PROCEEDINGS (2001)
Nilutamide: Possible utility as a second-line hormonal agent
A Desai et al.
UROLOGY (2001)
Is the flare phenomenon clinically significant?
GJ Bubley
UROLOGY (2001)
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action
P Limonta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
The genetics, pathophysiology, and management of human deficiencies of P450c17
RJ Auchus
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2001)
Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making
MG Oefelein et al.
UROLOGY (2000)
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup
P Iversen et al.
JOURNAL OF UROLOGY (2000)
Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the prostate cancer outcomes study
AL Potosky et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Intermittent androgen blockade in prostate cancer: Rationale and clinical experience
JM Wolff et al.
EUROPEAN UROLOGY (2000)
The history of endocrine therapy of benign and malignant diseases of the prostate
S Machtens et al.
WORLD JOURNAL OF UROLOGY (2000)
Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis
J Seidenfeld et al.
ANNALS OF INTERNAL MEDICINE (2000)
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia
DK Agarwal et al.
BJU INTERNATIONAL (2000)
Share Paper
